SELLAS Reports Data from Preclinical Studies Suggesting ASXL1 Mutations as Predictor of SLS009 Response in Solid Tumors
Shots:
- SELLAS tested SLS009 in 18 patient-derived cell lines (PDCs) at different concentrations to determine IC50 values and analyze ASXL1 mutations & other genetic markers, with predetermined high efficacy at IC50 <100 nM; (-ve control: untreated cell lines & revumenib at varying concentrations, +ve control: cell lines treated with staurosporine)
- ASXL1 mutations were seen 9 cell lines [CRC MSI-H: 58% (7/12) & NSCLC: 33% (2/6)], high SLS009 efficacy was seen in 67% (CRC MSI-H: 57% & NSCLC: 100%). No activity was seen with revumenib (negative control), & SLS009 outperformed staurosporine in 5/9 cell lines
- SELLAS has filed for provisional patent for using ASXL1 mutations as a predictive diagnostic to identify cancer patients
Ref: SELLAS | Image: SELLAS
Related News:- SELLAS Reports Results for SLS009 in P-IIa Trial for the Treatment of Acute Myeloid Leukemia (AML)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
